Anti Myelin Oligodendrocyte Glycoprotein Antibody Positivity C5139382
An autoimmune condition where antibodies target myelin, potentially causing demyelinating attacks in the brain and spinal cord. Management involves immunotherapy.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Optic neuritis
Transverse myelitis
Cortical encephalitis
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
ADEM-like presentation
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
High-dose intravenous corticosteroids
High-dose intravenous methylprednisolone is typically administered as first-line immunotherapy to rapidly suppress inflammatory demyelinating activity in MOG antibody-associated disease. This treatment aims to reduce antibody-mediated attack on myelin and decrease acute exacerbations.
Plasma exchange therapy
Therapeutic plasma exchange removes pathogenic antibodies including anti-MOG antibodies from circulation and is particularly useful during acute relapses or when corticosteroids are contraindicated or ineffective.
Additional treatment options
Intravenous immunoglobulin (IVIG)
IVIG provides immunomodulatory effects by modulating antibody production and inhibiting complement activation, serving as an alternative immunotherapy option particularly for patients who cannot tolerate corticosteroids.
medicationNeurorehabilitation program
Structured physical therapy focuses on improving motor function, balance, and coordination affected by demyelinating lesions. Therapy is tailored to individual deficits and may include gait training, strengthening exercises, and endurance activities.
physical_therapyRegular MRI surveillance
Periodic magnetic resonance imaging monitoring is essential to track disease activity, lesion burden, and response to treatment. MRI helps identify subclinical relapses and guides therapeutic decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Myelin Oligodendrocyte Glycoprotein Antibody Positivity C5139382?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Banwell B, Hacohen Y, Rostasy K, Tardieu M, Pohl D. Myelin oligodendrocyte glycoprotein antibody disease in children: Clinical practice guidelines. Neurology. 2021;96(8):382-394.
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B. Clinical spectrum and long-term prognosis of patients with MOG antibodies. JAMA Neurol. 2020;77(8):1021-1031.
Reindl M, Waters P, Berger T, Marignier R, Dale RC. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102.
Chen J, Wang Q, Li H, Zhang J, Xu Y. Treatment outcomes in MOG antibody-associated disease: A systematic review and meta-analysis. Mult Scler J. 2022;28(11):1721-1734.
Medication Comparisons
Compare medications used to treat Anti Myelin Oligodendrocyte Glycoprotein Antibody Positivity C5139382. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy